Prof. Shinya Kimura
Saga University, Japan
Email: shkimu@cc.saga-u.ac.jp
Qualifications
2009 Professor and Chairman, Department of Internal Medicine
2000 Postdoctoral Fellow, Frankfurt University
1996 Postdoctoral Fellow, The Walter and Eliza Hall Institute
1990 Research Fellow, Kyoto Prefectural University of Medicine
Publications (Selected)
-
Fukushima N, Itamura H, Urata C, Tanaka M, Hisatomi T, Kunota Y, Sueoka E, Kimura S. Clinical presentation and outcome in patients of over 75 years old with malignant lymphoma. Int J Clin Med, in press.
-
Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S. A non-invasive system for monitoring resistance to EGFR tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol, in press.
-
Kawatani M, Takayama H, Muroi M, Kimura S, Maekawa T. Osada H. (2011) Identification of a small molecule inhibitor of DNA topoisomerase II by proteomic profiling. Chem Biol, 18(6):743-51.
-
Hisatomi T, Sueoka-Aragane N, Sato A, Tomimasu R, Ide M, Kunimasa A, Okamoto K, Kimura S, Sueoka E. (2011) NK314 potentiates anti-tumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIa and DNA-dependent protein kinase. Blood, 117(13):3575-84.
-
Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyon JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T. (2010) Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood, 116: 2089-2095.
-
Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka R, Nagao R, Nakahara T, Fujiyama Y, Maekawa T. (2010) Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in hypoxic environment. Cell Death Diff. 17(7):1211-20.
-
Kantarjian H, le Coutre P, Cortes J, Pinilla-lbarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. (2010) Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer, 116(11): 2665-72.
-
Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, Habuchi T, Maekawa T, Kimura S. (2009) Intravesical administration of T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immun 58: 493-502.
-
Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Yoshikawa T, Maekawa T, Nakahata T, Adachi S. (2008) Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Diff, 15: 1712-22.
-
Kuroda J, Kimura S, Strasser A, Andreeff M, O’Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. (2007) Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Diff, 14: 1667-77.
-
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. (2007) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood, 109: 306-14.
-
Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106: 3948-54.
Profile Details
Last Updated: August, 2012.
Reference this profile directly: NULL